MSD and Cipla announce Partnership to Co-market MSD’s raltegravir 400mg tablet for Indian Market

MSD that holds patent for HIV drug Raltegravir , has announced strategic partnership with Cipla to market, promote and distribute 400mg tablet of this drug in India. Raltegravir is used to treat patients who have developed resistance to both first and second line regimen.

See the press release issued jointly by Cipla and MSD here

This entry was posted in Patents. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s